ClinicalTrials.gg
CompletedNCT00622336Updated Nov 20, 2019Results posted

A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma

A Phase 3 interventional study of CC-5013 and Lenalidomide in Multiple Myeloma, sponsored by Celgene. Completed at 7 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-20.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years 10 months after the study started (first participant enrolled Apr 2003, registered Feb 2008).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
330
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 249 studies testing lenalidomide in Multiple Myeloma — 29 open to participants now, 70 under way, 14 of them phase 3. Lenalidomide · Multiple Myeloma.

Enrollment
32nd of 249
330 · median 50
Started
2003
with 3 others
Phase 3
44 of 249
3 open now
Registered
41st of 249
by date
Lead sponsor
14 of 249
Celgene

Among the 249 studies testing lenalidomide in Multiple Myeloma, this one is the 32nd largest by enrollment, is one of 4 that started in 2003, is one of 44 in phase 3, and was the 41st registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

29 of the 249 studies testing lenalidomide in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

24 more — sign in →

By country, each count listing its studies:

All 29 open studies →

About lenalidomide

Lenalidomide: first FDA approval 2005 (REVLIMID), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 249 studies testing lenalidomide in Multiple Myeloma, or all of them as a file.
02

Study summary

The study evaluated the safety of Lenalidomide monotherapy in participants with advanced multiple myeloma who had discontinued treatment with combination thalidomide plus high-dose dexamethasone or high-dose dexamethasone alone in studies Thal-MM-003, CC-5013-MM-009 and CC-5013-MM-010 due to the development of documented disease progression or the inability to tolerate the lowest dosing regimen per previous protocol of thalidomide and/or high-dose dexamethasone without grade 3 or 4 toxicity.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Multiple Myeloma
  • Revlimid
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Understand and voluntarily sign an form.
  • Age ≥ 18 years at time of signing the informed consent form.
  • Able to adhere to the study visit schedule and other protocol requirements
  • Participants with multiple myeloma and were enrolled in either THAL-MM-003, CC-5013-MM-009, or CC-5013-MM-010 and discontinued study therapy with thalidomide and high-dose dexamethasone or high-dose dexamethasone alone due to:

documented disease progression OR inability to tolerate the lowest dosing regimen allowed on previous protocol without a grade 3 or 4 toxicity.

  • (ECOG) performance status score 0,1,2
  • Recovery from thalidomide or dexamethasone-related toxicity to ≤ grade 2 (NCI CTC)
  • Females of (FCBP) must agree to using two methods of

Exclusion criteria

Exclusion Criteria:

  • Prior development of a ≥ grade 2 allergic reaction/ or prior development of a grade ≥ 3 rash or desquamation while taking thalidomide National Cancer Institute Common toxicity Criteria (NCI CTC)
  • Use of any standard/experimental anti-myeloma therapy within 28 days of randomization or use of any experimental non-drug therapy within 56 days of initiation of drug treatment
  • Any serious medical condition, laboratory abnormality, or psychiatric illness that will prevent the participant from signing the form or that will place the participant at an unacceptable risk for toxicity if he/she participates in the study.
  • Pregnant or lactating females.
  • Prior therapy with CC-5013; prior history of , other than multiple myeloma (except basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast), unless subject has been free of disease for ≥ 5 years
  • More than 4 months has elapsed since the last dose of study drug was administered on study Tal MM-003, CC-5013-MM-009, CC-5013-MM-010
  • (ANC) \<1,000cells/mm\^3 (1.0 X 10\^9/L)
  • count \<75,000/mm\^3 (30 X 10\^9/L) for those with \<50% if the bone marrow nucleated cells re plasma cells; Platelet count \<30,000/mm\^3 (30 X 10\^9/L) for those with \<50% if the bone marrow nucleated cells re plasma cells
  • Serum creatinine >2.5mg/dL; serum /AST or SGPT/ALT x (ULN)
  • Serum total >2.0mg/d/L
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
330 participants (actual)

Study arms

  • Experimental
    Lenalidomide 25mg (CC-5013)

    Oral 25mg daily on Days 1-21 every 28 days

    Drug: CC-5013 · Drug: Lenalidomide

Interventions

  • Oral 25mg daily on Days 1-21 every 28 days.

    Also known as: Revlimid, lenalidomide

  • Oral Lenalidomide 25mg daily on Days 1-21 every 28 days.

    Also known as: Revlimid, CC-5013

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AE) During the Treatment Phase

    An AE is any sign, symptom, illness, or diagnosis (either observed or volunteered) that appears or worsens during the course of the study Serious adverse event (SAE) = any AE which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect; constitutes an important medical event. A treatment emergent AE is defined as any AE occurring or worsening on or after the first dose of study drug and within 30 days after the last dose of study drug. Safety and severity was assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 2.0; Severity of AEs were graded (including second primary malignancies) as Grade 1- Mild; Grade 2- Moderate; Grade 3- Severe; Grade 4- Life-threatening; Grade 5-Fatal;

    Time frame: Until data cut-off of 22 Oct 2009; AEs/SAEs were recorded from informed consent to 30 days post treatment discontinuation visit. Maximum exposure to Lenalidomide treatment was 1260 days.

  2. Number of Participants With Adverse Events (AE) During the Extension Phase

    An AE is any sign, symptom, illness, or diagnosis (either observed or volunteered) that appears or worsens during the course of the study Serious adverse event (SAE) = any AE which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect; constitutes an important medical event. A treatment emergent AE is defined as any AE occurring or worsening on or after the first dose of study drug and within 30 days after the last dose of study drug. Safety and severity was assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 2.0; Severity of AEs were graded (including second primary malignancies) as Grade 1- Mild; Grade 2- Moderate; Grade 3- Severe; Grade 4- Life-threatening; Grade 5-Fatal;

    Time frame: From 22 Oct 2009 to November 2013; AEs/SAEs were recorded from informed consent to 30 days post treatment discontinuation visit.

Secondary outcomes

  1. Time to Progression

    Time to progression based on the myeloma response determination criteria developed by Bladé et al 1998 and is defined as the time from registration to the first documented progression. The progressive disease criteria included increasing monoclonal paraprotein levels, bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia.

    Time frame: Up to 70 months

  2. Myeloma Response Rate

    Myeloma response determination criteria developed by Bladé et al 1998. Complete Response (CR):Disappearance of monoclonal paraprotein. Remission Response (RR):75-99% reduction in monoclonal paraprotein/90-99% reduction in 24-hr urinary light chain excretion. Partial Response (PR):50-74% reduction in monoclonal paraprotein/50-89% reduction in 24-hr urinary light chain excretion. Stable Disease (SD):Criteria for PR or PD not met. Plateau Phase:If PR, stable monoclonal paraprotein (within 25% above or below nadir)/stable soft tissue plasmacytomas. Progressive Disease (PD):Disease worsens.

    Time frame: Up to 70 months

  3. Duration of Response

    Duration of response based on the Myeloma response determination criteria developed by Bladé et al 1998 and defined as time from the initial documented response (partial response or better) to confirmed disease progression, based on International Myeloma Working Group (IMWG) criteria.

    Time frame: Up to 70 months

07

Results

Posted Dec 30, 2014

Participant flow

This was an international, open-label single arm study of oral lenalidomide in participants with multiple myeloma who had previously received high dose dexamethasone alone or in combination with thalidomide in the study NCT 00057564, or previously received high dose dexamethasone alone in studies NCT 00056160 and NCT 00424047.

Treatment Phase
Participant flow — Treatment Phase
MilestoneLenalidomide 25mg
Started330
Safety population330
Completed21
Not completed309
Withdrew: Progression of disease181
Withdrew: Adverse event46
Withdrew: Other40
Withdrew: Death14
Withdrew: Lack of therapeutic effect13
Withdrew: Withdrawal by subject13
Withdrew: Lost to follow-up2
Extension Phase
Participant flow — Extension Phase
MilestoneLenalidomide 25mg
Started21
Completed0
Not completed21
Withdrew: Adverse event2
Withdrew: Progressive disease6
Withdrew: Lack of therapeutic effect2
Withdrew: Withdrawal by subject1
Withdrew: Lost to follow-up1
Withdrew: Other9

Outcome measures

PrimaryNumber of Participants With Adverse Events (AE) During the Treatment Phase

An AE is any sign, symptom, illness, or diagnosis (either observed or volunteered) that appears or worsens during the course of the study Serious adverse event (SAE) = any AE which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect; constitutes an important medical event. A treatment emergent AE is defined as any AE occurring or worsening on or after the first dose of study drug and within 30 days after the last dose of study drug. Safety and severity was assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 2.0; Severity of AEs were graded (including second primary malignancies) as Grade 1- Mild; Grade 2- Moderate; Grade 3- Severe; Grade 4- Life-threatening; Grade 5-Fatal;

Time frame:
Until data cut-off of 22 Oct 2009; AEs/SAEs were recorded from informed consent to 30 days post treatment discontinuation visit. Maximum exposure to Lenalidomide treatment was 1260 days.
Reported as:
Number · participants
Number of Participants With Adverse Events (AE) During the Treatment Phase
participantsLenalidomide 25mg (CC-5013)
Adverse Event (AE)327
Adverse Event related to study drug268
Adverse Event NCI CTC (Version2.0) Grade 3 or 4256
Serious Adverse Event (SAE)177
AE leading to discontinuation of study drug52
AE leading to dose reduction/interruption210
SecondaryTime to Progression

Time to progression based on the myeloma response determination criteria developed by Bladé et al 1998 and is defined as the time from registration to the first documented progression. The progressive disease criteria included increasing monoclonal paraprotein levels, bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia.

Time frame:
Up to 70 months

No measurements were reported for this outcome.

SecondaryMyeloma Response Rate

Myeloma response determination criteria developed by Bladé et al 1998. Complete Response (CR):Disappearance of monoclonal paraprotein. Remission Response (RR):75-99% reduction in monoclonal paraprotein/90-99% reduction in 24-hr urinary light chain excretion. Partial Response (PR):50-74% reduction in monoclonal paraprotein/50-89% reduction in 24-hr urinary light chain excretion. Stable Disease (SD):Criteria for PR or PD not met. Plateau Phase:If PR, stable monoclonal paraprotein (within 25% above or below nadir)/stable soft tissue plasmacytomas. Progressive Disease (PD):Disease worsens.

Time frame:
Up to 70 months

No measurements were reported for this outcome.

SecondaryDuration of Response

Duration of response based on the Myeloma response determination criteria developed by Bladé et al 1998 and defined as time from the initial documented response (partial response or better) to confirmed disease progression, based on International Myeloma Working Group (IMWG) criteria.

Time frame:
Up to 70 months

No measurements were reported for this outcome.

PrimaryNumber of Participants With Adverse Events (AE) During the Extension Phase

An AE is any sign, symptom, illness, or diagnosis (either observed or volunteered) that appears or worsens during the course of the study Serious adverse event (SAE) = any AE which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect; constitutes an important medical event. A treatment emergent AE is defined as any AE occurring or worsening on or after the first dose of study drug and within 30 days after the last dose of study drug. Safety and severity was assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 2.0; Severity of AEs were graded (including second primary malignancies) as Grade 1- Mild; Grade 2- Moderate; Grade 3- Severe; Grade 4- Life-threatening; Grade 5-Fatal;

Time frame:
From 22 Oct 2009 to November 2013; AEs/SAEs were recorded from informed consent to 30 days post treatment discontinuation visit.
Reported as:
Number · participants
Number of Participants With Adverse Events (AE) During the Extension Phase
participantsLenalidomide 25mg (CC-5013)
≥ 1 Adverse Event (AE)13
Adverse Event related to study drug1
Adverse Event NCI CTC (Version2.0) Grade 3 or 45
≥ 1 Serious Adverse Event (SAE)5
≥ 1 AE leading to discontinuation of study drug1
≥ 1 AE leading to dose reduction/interruption3

Adverse events

Collected over From first dose of study drug through to 30 days after the last dose, until the data cut-off date of 11 November 2013. Maximum time on Lenalidomide treatment was 1260 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lenalidomide (Treatment Phase) Up to Data Cut-off 22 Oct 2009—177/330 (53.6%)0/330 (0%)
Lenalidomide ( ExtensionPhase) 22 Oct 2009 to 11 November 2013—5/21 (23.8%)6/21 (28.6%)
Most frequent serious events
Showing 10 of 180
Most frequent serious events
EventLenalidomide (Treatment Phase) Up to Data Cut-off 22 Oct 2009Lenalidomide ( ExtensionPhase) 22 Oct 2009 to 11 November 2013
Pneumonia NOSInfections and infestations38/3302/21
Urinary tract infection NOSInfections and infestations1/3301/21
Anaemia NOSBlood and lymphatic system disorders11/3301/21
General physical health deteriorationGeneral disorders1/3301/21
Diarrhoea NOSGastrointestinal disorders3/3301/21
Inguinal hernia NOSGastrointestinal disorders1/3301/21
Bronchitis NOSRespiratory, thoracic and mediastinal disorders3/3301/21
Cardiac failure congestiveCardiac disorders2/3301/21
Renal failure acute or chronicRenal and urinary disorders2/3301/21
Anaemia of Malignant DiseaseNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3301/21
Most frequent other events
Most frequent other events
EventLenalidomide (Treatment Phase) Up to Data Cut-off 22 Oct 2009Lenalidomide ( ExtensionPhase) 22 Oct 2009 to 11 November 2013
AstheniaGeneral disorders0/3303/21
HeadacheNervous system disorders0/3303/21
Anaemia NOSBlood and lymphatic system disorders0/3302/21

Baseline characteristics

Age, Continuous
Age, Continuous(years)Lenalidomide 25mg (CC-5013)
Mean63.3 ± 9.43
Age, Customized
Age, Customized(participants)Lenalidomide 25mg (CC-5013)
> 65 years136
≤ 65 years194
Sex: Female, Male
Sex: Female, Male(Participants)Lenalidomide 25mg (CC-5013)
Female137
Male193
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Lenalidomide 25mg (CC-5013)
Asian/Pacific Islander2
Black or African American14
White309
Hispanic5
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(participants)Lenalidomide 25mg (CC-5013)
0 = Fully Active95
1 = Restricted Activity178
2 = Ambulatory; not able to work44
3 = Limited Self Care1
4 = Completely Disabled0
Missing= Unspecified12
08

Study locations

7 sites
  • Republican Clinical Hospital #1
    Izhevsk, 426039, Russian Federation
  • Nizhny Novgorod Clinical Hospital n.a.Semashko
    Nizhny Novgorod, 603126, Russian Federation
  • Novosibirsk State Regional Clinical
    Novosibirsk, 630087, Russian Federation
  • Samara Regional Clinical Hospital
    Samara, 443095, Russian Federation
  • Kharkov Postgraduate Medical Academy Kharkov Regional Clinical
    Kharkov, 61070, Ukraine
  • Institute of Hematology and Transfusiology of the UAMS Department of blood diseases
    Kiev, 04060, Ukraine
  • Odessa Regional Clinical Hospital
    Odessa, 65025, Ukraine
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2003 to primary completion in Nov 2013, 127 months.

Results were first posted in Dec 2014, 1 year 1 month after primary completion.

Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 127 months is above that.

Counting every sponsor, half of 178 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2008
First posted
Feb 25, 2008
StartActual
Apr 1, 2003
Primary completionActual
Nov 25, 2013
CompletionActual
Nov 25, 2013
Results first posted
Dec 30, 2014
Last update
Nov 20, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00622336
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Feb 25, 2008
Start date
Apr 1, 2003
Primary completion
Nov 25, 2013
Completion
Nov 25, 2013
Results posted
Dec 30, 2014
Last update
Nov 20, 2019

Study contacts

Robert Knight, MD
study director · Celgene Corporation

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenalidomide

Start the discussion